Peptide-mediated cellular delivery

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 2, 2000, Pages 162-167

  Schwartz, John J ^a   Zhang, Shuguang ^a  

^a Massachusetts Institute of Technology   (United States)

Author keywords

Antennapedia; Membrane translocation; Molecular engineering; Non viral delivery; TAT; VP22

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; OLIGONUCLEOTIDE; PEPTIDE; PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

DROSOPHILA; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; GENETIC ENGINEERING; HERPES VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; TARGET CELL;

ANIMALS; ANTENNAPEDIA HOMEODOMAIN PROTEIN; DRUG DELIVERY SYSTEMS; GENE PRODUCTS, TAT; GENE THERAPY; HOMEODOMAIN PROTEINS; HUMANS; NUCLEAR PROTEINS; PEPTIDES; TRANSCRIPTION FACTORS; VIRAL PROTEINS;

HERPES; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034001783     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Anderson WF: Human gene therapy. Nature (1998) 392(Suppl 6679):25-30.
2. Ennist DL: Gene therapy for lung disease. Trends Pharmacol Sci (1999) 20:260-266.
3. Vassalli G, Dichek DA: Gene therapy for arterial thrombosis. Cardiovasc Res (1997) 35:459-469.
4. Lewis BS, Flugelman MY, Weisz A, Keren-Tal I, Schaper W: Angiogenesis by gene therapy: A new horizon for myocardial revascularization? Cardiovasc Res (1997) 35:490-497.
5. Yla-Herttuala S: Vascular gene transfer. Curr Opin Lipidol (1997) 8:72-76.
6. Gorecki DC, MacDermot KD: Gene therapy: Panacea or placebo? II. Main applications of gene therapy. Arch Immunol Ther Exp (1997) 45:375-381.
7. Norman TC, Smith DL, Sorger PK, Drees BL, O'Rourke SM, Hughes TR, Roberts CJ, Friend SH, Fields S, Murray AW: Genetic selection of peptide inhibitors of biological pathways. Science (1999) 285:591-595.
8. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A: Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science (1999) 285:2129-2133.
9. Erbacher P, Remy JS, Behr JP: Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther (1999) 6:138-145.
10. Ferrari S, Pettenazzo A, Garbati N, Zacchello F, Behr JP, Scarpa M: Polyethylenimine shows properties of interest for cystic fibrosis gene therapy. Biochim Biophys Acta (1999) 1447:219-225.
11. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR: Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice. Hum Gene Ther (1999) 10:2615-2626.
12. Pack DW, Putnam D, Langer R: Design of imidazole-containing endosomolytic biopolymers for gene delivery. Biotechnol Bioeng (2000) 67:217-223.
13. Hershfield MS: Adenosine deaminase deficiency: Clinical expression, molecular basis and therapy. Semin Hematol (1998) 35:291-298.
14. Hoogerbrugge PM, von Beusechem VW, Kaptein LC, Einerhand MP, Valerio D: Gene therapy for adenosine deaminase deficiency. Br Med Bull (1995) 51:72-81.
15. Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D: Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther (1996) 3:179-183.
16. Zanta MA, Belguise-Valladier P, Behr JP: Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA (1999) 96:91-96.
17. Plank C, Tang MX, Wolfe AR, Szoka FC: Branched cationic peptides for gene delivery: Role of type and number of cationic residues in formation and In vitro activity of DNA polyplexes. Hum Gene Ther (1999) 10:319-332.
18. Knight A, Carvajal J, Schneider H, Coutelle C, Chamberlain S, Fairweather N: Non-viral neuronal gene delivery mediated by the HC fragment of tetanus toxin. Eur J Biochem (1999) 259:762-769.
19. Ziady AG, Ferkol T, Gerken T, Dawson DV, Perlmutter DH, Davis PB: Ligand substitution of receptor targeted DNA complexes affects gene transfer into hepatoma cells. Gene Ther (1998) 5:1685-1697.
20. Wadhwa MS, Collard WT, Adami RC, McKenzie DL, Rice KG: Peptide-mediated gene delivery: Influence of peptide structure on gene expression. Bioconjug Chem (1997) 8:81-88.
21. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science (1999) 285:1569-1572.
22. Derossi D, Chassaing G, Prochiantz A: Trojan peptides: The penetratin system for intracellular delivery. Trends Cell Biol (1998) 8:84-87.
23. Williams EJ, Dunican DJ, Green PJ, Howell FV, Derossi D, Walsh FS, Doherty P: Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide. J Biol Chem (1997) 272:22349-22354.
24. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezael K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T, Bartfai T, Langel U: Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission In vivo. Nature Biotechnol (1998) 16:857-861.
25. Mahato RI, Smith LC, Rolland A: Pharmaceutical perspectives of non-viral gene therapy. Adv Genet (1999) 41:95-156.
26. Harbottle RP, Cooper RG, Hart SL, Ladhoff A, McKay T. Knight AM, Wagner E, Miller AD, Coutelle C: An RGD-oligolysine peptide: A prototype construct for integrin-mediated gene delivery. Hum Gene Ther (1998) 9:1037-1047.
27. Shewring L, Collins L, Lightman SL, Hart S, Gustafsson K, Fahre JW: A non-viral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins. Transplantation (1997) 64:763-769.
28. Aldrian-Herrada G, Desarmenien MG, Orcel H, Boissin-Agasse L, Mery J, Brugidou J, Rabie A: A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucl Acid Res (1998) 26:4910-4916.
29. Avrameas A, Temynck T, Gasmi L, Buttin G: Efficient gene delivery by a peptide derived from a monoclonal anti-DNA antibody. Bioconjug Chem (1999) 10:87-93.
30. Schneider H, Harbottle RP, Yokosaki Y, Jost P, Coutelle C: Targeted gene delivery into α9β1-integrin-displaying cells by a synthetic peptide. FEBS Lett (1999) 458:329-332
31. Morris MC, Chaloin L, Mery J, Heitz F, Divita G: A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucl Acid Res (1999) 27:3510-3517.
32. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G: A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucl Acid Res (1997) 25:2730-2736.
33. Niidome T, Takaji K, Urakawa M, Ohmori N, Wada A, Hirayama T, Aoyagi H: Chain length of cationic α-helical peptide sufficient for gene delivery into cells. Bioconjug Chem (1999) 10:773-780.
34. Singh D, Bisland SK, Kawamura K, Gariepy J: Peptide-based intracellular shuttle able to facilitate gene transfer in mammalian cells. Bioconjug Chem (1999) 10:745-754.
35. Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 272:16010-16017.
36. Kam J: Tackling Tat. J Mol Biol (1999) 293:235-254.
37. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B: Anglogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA (1995) 92:4838-4842.
38. Taraboletti G, Benelli R, Borsotti P, Rusnati M, Presta M, Giavazzi R, Ruco L, Albini A: Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. J Pathol (1999) 188:76-81.
39. Efthymiadis A, Briggs LJ, Jans DA: The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties. J Biol Chem (1998) 273:1623-1628.
40. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA (1994) 91:664-648.
41. Dorn A, Affolter M, Gehring WJ, Leupin W: Homeodomain proteins in development and therapy. Pharmacol Ther (1994) 61:155-184.
42. Elliott G, O'Hare P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 88:223-233.
43. Elliott G, O'Hare P: Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther (1999) 6:149-151.
44. Phelan A, Elliott G, O'Hare P: Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nature Biotechnol (1998) 16:440-443.
45. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Edvard Smith CI, O'Hare P: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther (1999) 6:12-21.
46. Derer W, Easwaran HP, Knopf CW, Leonhardt H, Cardoso MC: Direct protein transfer to terminally differentiated muscle cells. J Mol Med (1999) 77:609-613.
47. Luft FC: Can VP22 resurrect gene therapy? J Mol Med (1999) 77:575-576.
48. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell (1997) 88:323-331.
49. Levine AJ: The tumor suppressor genes. Annu Rev Biochem (1993) 62:623-651.
50. Koelle DM, Frank JM, Johnson ML, Kwok WW: Recognition of herpes simplex virus type 2 tegument proteins by CD4 T-cells infiltrating human genital herpes lesions. J Virol (1998) 72:7476-7483.
51. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature (1996) 380:364-366.
52. Roberts RW, Szostak JW: RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci USA (1997) 94:12297-12302.
53. Roberts RW: Totally in vitro protein selection using mRNA-protein fusions and ribosome display. Curr Opin Chem Biol (1999) 3:268-273.